DIA Opts for Paris in the Springtime
Ella Fitzgerald always loved Paris in the springtime, and the Drug Information Association (DIA) is now hoping the French capital will prove to be an irresistible lure for the pharmaceutical industry. For the 27th DIA Annual EuroMeeting, organizers have switched the event from its usual late March slot to mid-April in 2015.
The congress will look at some of the major challenges facing global health today, including the need to come together to drive innovation. The opportunity of the Innovative Medicines Initiatives (IMI) and other public-private partnerships are formative mechanisms that must be maximized in Europe and other regions, program chairs note.
Discussion at the meeting will concentrate on how early and harmonized regulatory dialogue is necessary to ensure clinical development that is more efficient and will accelerate access to novel therapies for patients. The role of the European Union's new clinical trials legislation will come under scrutiny in the meeting's opening track on access to innovative treatments.
Another track will look at special development pathways in pediatrics, the elderly, and in pregnancy. Nearly 10 years after the adoption of the Paediatric Regulation, substantial experience has been gained, yet science continues to evolve in this area and raises new questions to be answered in the future. At the same time, the need for global convergence has become evident in several areas. Also, the speed of traditional development concepts is slower than the speed of ageing in European society, according to the theme leaders.
Further parallel sessions will focus on innovation in vaccine development, medical devices, and combination products, novel treatments for rare diseases, availability of medicinal products/drug shortages, pharmacovigilance, big data, and mobile health, among other areas.
Paris has a rich history of medical innovation. Local scientists and clinicians have changed modern medicine through the discovery of instruments such as the stethoscope and hypodermic needle, treatments like antibiotics or antipsychotics, vaccines against tuberculosis and rabies, and the discovery of diseases such as HIV.
-Philip Ward
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
